

**ASX ANNOUNCEMENT**

**Shares released from escrow**

**3 August 2009, Sydney, Australia**

Medical Therapies Limited (ASX:MTY) advises that 2,000,000 ordinary shares owned by Cell Signals have been released from escrow. Cell Signals is the original developer and vendor of the midkine technology assets which were acquired by MTY on 16 April 2008.

Cell Signals has a total of 35,000,000 shares in Medical Therapies Limited of which 33,000,000 will remain escrowed.

end

**About Medical Therapies Limited (ASX: MTY):**

Medical Therapies Limited is a biotechnology company listed on the Australian Stock Exchange. The Company is the owner of the largest intellectual property portfolio around midkine globally. Midkine is a significant novel therapeutic and diagnostic target. MTY's core strategy is deliver early revenue by developing its diagnostic portfolio to market and license out its therapeutic portfolio to suitable partners.

Midkine is a native protein expressed during early cancer formation as well as at the onset of inflammatory processes. Medical Therapies is committed to the commercialisation of its novel cancer diagnostic assets to improve therapeutic outcome. In addition to its in-house diagnostic product development program MTY is actively seeking partnership opportunities for its non-core therapeutic and diagnostic assets.

*For further information visit [www.medicaltherapies.com.au](http://www.medicaltherapies.com.au) or contact:*

Maria Halasz  
CEO  
M +61 416 008 413

**Investment in biotechnology companies**

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Medical Therapies recommends that investors seek professional advice before making an investment in its shares.